12th Congress of the European Hematology ... - Haematologica

12 th Congress of the European Hematology Association
MPDs. We studied 17 patients with MPDs, 9 of them experienced ET,
5 PV and 3 IMF. Results. 7 out of 9 patients with ET, 1 out of 2 patients
with PV and 2 out of 3 patients with IMF were JAK 2 V617F positive.
We found that the patients who were positive for the V617F mutation
had also increased levels of VEGF in both serum and immunohistochemical
proportions of bone marrow, compared to the MPD patients
with the JAK2 wild type. Higher levels of VEGF in both the serum and
bone marrow were found in MPD patients than in controls. The statistical
analysis showed that, in patients with JAK2 wild type, the
mean±SD level of serum VEGF was calculated 639±594.3 pg/mL, whereas
in JAK2 V617F patients, the serum VEGF level was 1001±528.4 pg/mL.
The medial levels for VEGF in serum were 539 pg/mL for the JAK2 wild
type patients and 866 pg/mL for the JAK2 V617F patients. Regarding the
immunohistochemical VEGF expression in bone marrow, the mean±SD
level was counted 23.75± 10.3% for the patients with JAK2 wild type
and in JAK2 V617F patients the mean level was 37.14± 9.9%. The median
levels were 20% for the JAK2 wild type patients and 30% for the
JAK2 V617F patients. Conclusions. These results are suggestive of an
important role of angiogenesis and apoptosis in MPDs. Those two procedures
are likely to influence each other and we are not yet sure which
of those events is the promoter for the other. It also seems that they play
a crucial role in the pathogenesis and prognosis as well as in the duration
of the diseases and transformation to acute leukemia. They probably
are two of the key points towards the therapeutic options of MPDs.
This finding puts forward the use of targeted therapies, such as anti-
VEGF antibodies in MPD patients.
1552
RECLASSIFICATION OF HAEMATOLOGICAL MALIGNANCIES ACCORDING
MORPHOLOGY DATA
M. Giraldo, 1 P. Latre, 2 E. Franco-García, 3 R. Alvarez, 4 J. Pascual, 4
C. Martos5 1 Miguel Servet University Hospital, ZARAGOZA; 2 FEETEG, ZARAGOZA,
Spain; 3 FEHHA, ZARAGOZA; 4 Hospital U Miguel Servet, ZARAGOZA;
5 Aragon Health Department, ZARAGOZA, Spain
Background and Aims. Related to the HAEMACARE project we pretend
revise the codes of Zaragoza population cancer registry in order to
increase availability and standardisation of morphology data, ensuring
a strict adherence to ICD-O classification assess the distribution of the
haematological malignancies as lymphoid neoplasms, acute and chronic
myeloid leukaemias and multiple myeloma. Patients and Method. From
January 1996 to December 2000, 2,852 patients diagnosed with haematological
malignancies were recruited from different sources: the population-based
Cancer Registry of Zaragoza, Registry of haematological
malignancies of FEHHA and Miguel Servet Hospital records. Former
pathological and hematological diagnoses were reviewed and some
were prospectively reclassified following the latest WHO classification
and their histological subtypes in accordance with the World Health
Organization (WHO) classification. We have estimate survival according
to specific morphology groups. Results. Following criteria established
by WHO classification the distribution of lymphoid neoplasms was as
follows: B-cell neoplasm 64.5%, T-cell neoplasm 3.3%, Hodgkin lymphoma
4.1%; Myelodisplastic syndromes 9.9%, acute lymphoblastic
leukaemia 1.9%, acute myeloid leukaemia 4.0%, chronic myeloid
leukaemia 2.3% and multiple myeloma 10.0%. Diffuse large B-cell lymphoma
(13.5%) and chronic B lymphoid leukaemia (9.3%) showed the
highest incidence rate in adults. Conclusions. A higher incidence rate of
lymphoid neoplasms was found in men in our area. We have observed
in the last period of study a tendency of survival differences.
548 | haematologica/the hematology journal | 2007; 92(s1)